Ulcerative Colitis Management Guidelines, Case-Based Learning, and Multidisciplinary IBD Care Are Driving Practice-Changing Education
By Corey Siegel, MD, MS
Co-Chair, Advances in IBD
New therapies and emerging evidence in IBD directly affect which treatment a patient should receive and when.
This urgency underpins the Advances in IBD annual meeting. Last year’s event delivered practical, practice-changing education, setting the stage for the 25th anniversary meeting taking place December 7-9, 2026, in Orlando.
What we saw in 2025 is a shift toward more proactive, individualized care—using biomarkers, patient history, and emerging therapies to guide earlier and more effective treatment decisions. This year we will emphasize individualized treatment approaches, emerging therapeutic strategies, and collaborative models of care.
What Made AIBD 2025 Impactful
The 2025 Advances in IBD Annual Meeting highlighted new data shaping how clinicians approach treatment selection and disease monitoring. Presentations included emerging evidence on therapeutic sequencing, the role of biomarkers in predicting response, and updated guidance on ulcerative colitis management emphasizing earlier intervention with advanced therapies. Faculty used case-based discussions to demonstrate how these findings translate into real-world decision-making.
Attendees were given structured approaches designed for direct use in patient care. These approaches focused on matching therapy to disease behavior and prior response while incorporating available biomarker information. Sessions highlighted specific decision points and explained the clinical rationale behind each option.
Throughout, the emphasis remained on helping clinicians refine judgment rather than simply reviewing data. If you missed the 2025 event, you can explore detailed coverage of these findings, including expert interviews and analysis, on the AIBD Learning Network.
What to Expect at the 25th Anniversary Meeting
The 25th anniversary meeting will deliver high-impact, practice-driven education that continues these themes. The educational program will include:
- Practical updates on Crohn’s disease and ulcerative colitis with emphasis on real-world treatment strategies
- Case-based sessions and interactive debates focused on therapy sequencing and complex clinical scenarios
- Focused clinical sessions on topics such as women’s health concerns in IBD and extraintestinal manifestations
- Dedicated learning pathways tailored by role, including for physicians, NPs, PAs, pharmacists, nurses, and trainees
- Operational insights on multidisciplinary care models and insurance navigation that support clinical workflow
These focus areas reflect the work clinicians face every day and reinforce Advances in IBD’s focus on translating evidence into care decisions.
Practical Gains for Clinicians
Participation in the Advances in IBD annual meeting supports measurable improvement in clinical thinking. Attendees leave with clearer sequencing strategies and a stronger framework for balancing treatment effectiveness with patient-specific risk.
I encourage colleagues committed to advancing their clinical practice to join me at this year’s meeting, where we will explore how emerging science informs the care decisions we make every day.
Event Details
- Event: Advances in IBD Annual Meeting
- Dates: December 7 to 9, 2026; Preconference Workshops December 6, 2026
- Location: Orlando, Florida
- Learn more on the event website
- 2026 event registration
Corey Siegel, MD, MS, is the Director of the Center for Digestive Health at Dartmouth Hitchcock Medical Center.